Pulmonx (LUNG) Projected to Post Earnings on Wednesday

Pulmonx (NASDAQ:LUNG - Get Free Report) is projected to announce its earnings results after the market closes on Wednesday, February 19th. Analysts expect the company to announce earnings of ($0.45) per share and revenue of $22.29 million for the quarter. Investors that wish to listen to the company's conference call can do so using this link.

Pulmonx Stock Down 5.6 %

Shares of NASDAQ:LUNG traded down $0.41 during midday trading on Friday, hitting $6.97. 196,602 shares of the company's stock were exchanged, compared to its average volume of 216,630. Pulmonx has a 12 month low of $5.46 and a 12 month high of $14.84. The company has a market cap of $275.25 million, a PE ratio of -4.74 and a beta of 0.64. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. The stock has a 50 day moving average price of $6.40 and a 200-day moving average price of $6.74.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Wells Fargo & Company dropped their target price on Pulmonx from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Wednesday, December 11th. Stifel Nicolaus cut their price objective on shares of Pulmonx from $17.00 to $16.00 and set a "buy" rating on the stock in a report on Thursday, October 31st. Finally, Citigroup reiterated a "neutral" rating and issued a $7.50 target price (down previously from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Pulmonx has a consensus rating of "Moderate Buy" and an average price target of $12.75.

Remove Ads

Insider Activity at Pulmonx

In other Pulmonx news, insider Geoffrey Beran Rose sold 4,376 shares of the firm's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $6.18, for a total value of $27,043.68. Following the completion of the sale, the insider now directly owns 291,057 shares of the company's stock, valued at $1,798,732.26. This trade represents a 1.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Glendon E. French III sold 20,000 shares of the company's stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $6.63, for a total value of $132,600.00. Following the transaction, the director now directly owns 1,071,974 shares in the company, valued at $7,107,187.62. This represents a 1.83 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,199 shares of company stock worth $208,859. 5.70% of the stock is owned by company insiders.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.